Upper GI 2016

MRC OEO 5 trial design

Patients with resectable

CF x2

Surgery

adenocarcinoma of oesophagus or type 1 and 2 oesophagogastric

TRIPLET vs. DOUBLET LONGER DURATION

ECX x4

Surgery

junction

• Primary endpoint: overall survival

• Final recruitment: 897 patients (this will provide 74%

power to detect a 7% improvement in 3 year survival (from 30% to 37%), or 84% power to detect an 8% improvement (to 38%)

• Recruitment completed 31 st October 2011

Alderson, Cunningham et al ASCO 2015